Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 43

1.

Comparative Analysis of Tat-Dependent and Tat-Deficient Natural Lentiviruses.

Bose D, Gagnon J, Chebloune Y.

Vet Sci. 2015 Sep 29;2(4):293-348. doi: 10.3390/vetsci2040293. Review.

2.

Chromatin Regulation and the Histone Code in HIV Latency
.

Turner AW, Margolis DM.

Yale J Biol Med. 2017 Jun 23;90(2):229-243. eCollection 2017 Jun. Review.

3.

HIV signaling through CD4 and CCR5 activates Rho family GTPases that are required for optimal infection of primary CD4+ T cells.

Lucera MB, Fleissner Z, Tabler CO, Schlatzer DM, Troyer Z, Tilton JC.

Retrovirology. 2017 Jan 24;14(1):4. doi: 10.1186/s12977-017-0328-7.

4.

Gene-expression reversal of lncRNAs and associated mRNAs expression in active vs latent HIV infection.

Nair M, Sagar V, Pilakka-Kanthikeel S.

Sci Rep. 2016 Oct 19;6:34862. doi: 10.1038/srep34862.

5.

Envelope-specific antibodies and antibody-derived molecules for treating and curing HIV infection.

Ferrari G, Haynes BF, Koenig S, Nordstrom JL, Margolis DM, Tomaras GD.

Nat Rev Drug Discov. 2016 Dec;15(12):823-834. doi: 10.1038/nrd.2016.173. Epub 2016 Oct 7. Review.

6.

Latency reversal and viral clearance to cure HIV-1.

Margolis DM, Garcia JV, Hazuda DJ, Haynes BF.

Science. 2016 Jul 22;353(6297):aaf6517. doi: 10.1126/science.aaf6517. Review.

7.

The BET inhibitor OTX015 reactivates latent HIV-1 through P-TEFb.

Lu P, Qu X, Shen Y, Jiang Z, Wang P, Zeng H, Ji H, Deng J, Yang X, Li X, Lu H, Zhu H.

Sci Rep. 2016 Apr 12;6:24100. doi: 10.1038/srep24100.

8.

Mechanisms of HIV Transcriptional Regulation by Drugs of Abuse.

Tyagi M, Bukrinsky M, Simon GL.

Curr HIV Res. 2016;14(5):442-454. Review.

9.

The effects of cocaine on HIV transcription.

Tyagi M, Weber J, Bukrinsky M, Simon GL.

J Neurovirol. 2016 Jun;22(3):261-74. doi: 10.1007/s13365-015-0398-z. Epub 2015 Nov 16. Review.

10.

Central memory CD4+ T cells are preferential targets of double infection by HIV-1.

Haqqani AA, Marek SL, Kumar J, Davenport M, Wang H, Tilton JC.

Virol J. 2015 Nov 11;12:184. doi: 10.1186/s12985-015-0415-0.

11.

Epigenetic control of HIV-1 post integration latency: implications for therapy.

Kumar A, Darcis G, Van Lint C, Herbein G.

Clin Epigenetics. 2015 Sep 24;7:103. doi: 10.1186/s13148-015-0137-6. eCollection 2015. Review.

12.

Post-transcriptional gene silencing, transcriptional gene silencing and human immunodeficiency virus.

Méndez C, Ahlenstiel CL, Kelleher AD.

World J Virol. 2015 Aug 12;4(3):219-44. doi: 10.5501/wjv.v4.i3.219. Review.

13.

The Tat Inhibitor Didehydro-Cortistatin A Prevents HIV-1 Reactivation from Latency.

Mousseau G, Kessing CF, Fromentin R, Trautmann L, Chomont N, Valente ST.

MBio. 2015 Jul 7;6(4):e00465. doi: 10.1128/mBio.00465-15.

14.

H3K27 Demethylation at the Proviral Promoter Sensitizes Latent HIV to the Effects of Vorinostat in Ex Vivo Cultures of Resting CD4+ T Cells.

Tripathy MK, McManamy ME, Burch BD, Archin NM, Margolis DM.

J Virol. 2015 Aug;89(16):8392-405. doi: 10.1128/JVI.00572-15. Epub 2015 Jun 3.

15.

Progress and challenges in the use of latent HIV-1 reactivating agents.

Shang HT, Ding JW, Yu SY, Wu T, Zhang QL, Liang FJ.

Acta Pharmacol Sin. 2015 Aug;36(8):908-16. doi: 10.1038/aps.2015.22. Epub 2015 Jun 1. Review.

16.

Targeting HIV transcription: the quest for a functional cure.

Mousseau G, Mediouni S, Valente ST.

Curr Top Microbiol Immunol. 2015;389:121-45. doi: 10.1007/82_2015_435. Review.

17.

Short chain fatty acids potently induce latent HIV-1 in T-cells by activating P-TEFb and multiple histone modifications.

Das B, Dobrowolski C, Shahir AM, Feng Z, Yu X, Sha J, Bissada NF, Weinberg A, Karn J, Ye F.

Virology. 2015 Jan 1;474:65-81. doi: 10.1016/j.virol.2014.10.033. Epub 2014 Nov 14.

18.

Defining differential genetic signatures in CXCR4- and the CCR5-utilizing HIV-1 co-linear sequences.

Aiamkitsumrit B, Dampier W, Martin-Garcia J, Nonnemacher MR, Pirrone V, Ivanova T, Zhong W, Kilareski E, Aldigun H, Frantz B, Rimbey M, Wojno A, Passic S, Williams JW, Shah S, Blakey B, Parikh N, Jacobson JM, Moldover B, Wigdahl B.

PLoS One. 2014 Sep 29;9(9):e107389. doi: 10.1371/journal.pone.0107389. eCollection 2014.

19.

Predicting the outcomes of treatment to eradicate the latent reservoir for HIV-1.

Hill AL, Rosenbloom DI, Fu F, Nowak MA, Siliciano RF.

Proc Natl Acad Sci U S A. 2014 Sep 16;111(37):13475-80. doi: 10.1073/pnas.1406663111. Epub 2014 Aug 5. Erratum in: Proc Natl Acad Sci U S A. 2014 Oct 28;111(43):15598.

20.

The histone deacetylase inhibitor vorinostat (SAHA) increases the susceptibility of uninfected CD4+ T cells to HIV by increasing the kinetics and efficiency of postentry viral events.

Lucera MB, Tilton CA, Mao H, Dobrowolski C, Tabler CO, Haqqani AA, Karn J, Tilton JC.

J Virol. 2014 Sep;88(18):10803-12. doi: 10.1128/JVI.00320-14. Epub 2014 Jul 9.

Supplemental Content

Support Center